Treatment of Stage 3 COVID-19 With Transcutaneous Auricular Vagus Nerve Stimulation Drastically Reduces Interleukin-6 Blood Levels: A Report on Two Cases

A 60-year-old male healthcare worker’s polymerase chain reaction (PCR) test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) nucleic acid was positive. On the day of the test, day 0, he presented with severe flu-like symptoms with body aches, weakness, and a fever of 99.8°F. His IL-6 blood level, taken at 10:00 am, was 2.7 pg/mL (reference <6.4). He had no significant preexisting comorbidities other than chronic allergic rhinitis and mild bilateral bronchiectasis. He was treated with azithromycin for three days. The flu-like symptoms resolved the next day, but on day 8, he presented with severe nonproductive coughing, fever, shortness of breath, and a blood oxygen saturation level of 94%. He also suffered general malaise, and his blood level of IL-6, taken before 11:00 am, was 76.4 pg/mL. Chest x-rays were unremarkable.

The patient received no treatment other than symptomatic paracetamol and codeine to reduce coughing, and he started using taVNS on day 8 as follows: The conchae of both ears were stimulated with a proprietary waveform (Xavant Technology, Silverton, South Africa), with the anode in one ear and the cathode in the other ear. The waveform delivers a 133-kHz decrescendo alternating current in bursts of 0.3 ms and 25 Hz. The taVNS application was initiated around 8:00 am every morning and lasted for 60 minutes per day. Blood for IL-6 blood level measurement was always collected before 11:00 am. The current was turned up until the patient could just feel it, usually around 4–5 mA. The patient did not receive supplemental oxygen or any other treatment. On day 11 (three days after starting taVNS), although still coughing severely, his saturation returned to 97%, and he generally felt better. On that day (day 11), his IL-6 was 44.1 pg/mL; his C-reactive protein (CRP), which was not measured previously, was 56 mg/mL (reference <5); his d-dimer was 0.35 mg/mL (reference 0–0.05); and his procalcitonin was <0.05 ng/mL (reference 0–0.05). Treatment with taVNS continued, and on day 14 (five days after starting taVNS), his IL-6 blood levels further declined to 28.0 pg/mL, his CRP was slightly reduced to 55 mg/mL, and he generally felt much better with reduced coughing. His body temperature was normal, and his saturation was between 97% and 98%. On day 16 (seven days after starting taVNS), he completely recovered from all symptoms; his IL-6 was 7.8 pg/mL, and his CRP was 19 mg/mL. The taVNS treatment was continued for another two days and then discontinued.

Another patient, a 64-year-old man with no preexisting comorbidities, presented with similar symptoms as the above patient, including severe coughing and malaise but abnormal lung x-rays and a core temperature of 100 °F. A nasopharyngeal swab for the PCR test for SARS-CoV-2 was negative; however, his clinical presentation and chest x-rays strongly indicated that he had COVID-19. He had flu-like symptoms seven days prior to presenting to the hospital that subsided the next day (day 0). Upon admission on day 7, his blood oxygen saturation was 93%, and he received oxygen supplementation. He also received azithromycin, vitamin A and D supplementation, one intravenous injection of 500 mg of methylprednisolone, and routine symptomatic treatment for his fever and cough. Additional treatment was provided with taVNS treatment identical to that of the above patient and initiated on day 7. His progress was similar to that of the patient described above, with blood IL-6 levels of 104.9 pg/mL and CRP of 264 mg/mL upon admission on day 7; 76.8 pg/mL and 54 mg/mL, respectively, on day 11 (day 4 of taVNS treatment); and an IL-6 blood value of 36.1 pg/mL on day 16. He recovered completely within ten days of admission (day 17), ten days after taVNS was initiated. Although the second patient received methylprednisolone upon admission, in both these patients, our care plan included the initiation of dexamethasone therapy immediately should the patients have shown clinical deterioration or if their IL-6 blood levels had increased or not decreased within 24 hours of starting taVNS. This therapy was not necessary in either of these patients.

The first patient followed the classical presentation through stages 1, 2, and 3 of the disease, while the second patient presented in stage 3 of the disease process when the viral load on the upper respiratory tract was lower or nonexistent. That was most likely the reason he tested negative on his PCR test taken from his nasopharynx. Sputum testing from his lungs may have provided a positive PCR test, but this was not performed. However, upon admission, there was no clinical doubt, supported by his x-ray picture and elevated IL-6 level, that he had stage 3 COVID-19. It is unknown if the steroid injection upon admission was responsible for reducing his IL-6 blood levels and caused him to recover. He did, however, follow the same pattern of recovery as the first patient who did not receive any enteral or parenteral steroids.

Staats et al. () proposed two mechanisms by which noninvasive VNS may help patients with respiratory involvement of COVID-19: bronchodilatation and activation of the cholinergic anti-inflammatory pathway (CAP). The CAP upregulates HMGB1, which regulates cytokine expression, leading to balancing of anti- and proinflammatory cytokines.

Transcutaneous VNS and taVNS () with comparable waveforms have shown positive effects on cytokines, and preliminary work was done in 2020 on their effects on controlling the “cytokine storm” associated with COVID-19 (). In all of the preliminary experience, no patient has reported adverse effects.

This form of treatment has not yet been proven to be effective in randomized controlled trials (RCTs) to treat the “cytokine storm” associated with SARS-CoV-2 infection. Although we fully appreciate the severe limitations of uncontrolled data, many new treatment modalities started off as single case reports or small case series (), followed by more specific case reports such as this one, which present more targeted metrics. This may be an example of a specific case report that advances the findings of previous reports and is also based on theoretical principles. Clearly, reports such as these should be followed by RCTs.

We, however, believe that taVNS should be used in addition to a patient’s regular care plan because it has no known adverse effects. We propose initial treatment with taVNS therapy and withholding steroid therapy for as long as the IL-6 levels decrease and the patient’s condition improves clinically because of the unfavorable side-effect profile of steroids in this scenario. Further scientific evaluation and RCTs are warranted prior to routine use of taVNS with this modality for the treatment of patients with COVID-19.

Drs. Boezaart and Botha both contributed substantially to the study concept and design, acquisition and analysis of data, and drafting and revising of the manuscript. All authors read and approved the final version of this manuscript.